Short Term Rating on Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX) : Zacks Investment Research ranks Celldex Therapeutics (CLDX) as 3, which is a Hold recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 9 research analysts is 1.89, which indicates as a Buy.

Celldex Therapeutics (CLDX) : 8 investment research analysts covering Celldex Therapeutics (CLDX) have an average price target of $8.63 for the near short term. The highest target price given by the Brokerage Firm to the stock is $24 and the lowest target is $3 for the short term. Analysts expect the variance to be within $6.89 of the average price.

For the current week, the company shares have a recommendation consensus of Buy.


Celldex Therapeutics (NASDAQ:CLDX): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.65 and $4.56 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.70. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.61, notching a gain of 0.88% for the day. The total traded volume was 1,608,249 . The stock had closed at $4.57 on the previous day.

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *